The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Olatuton 30 mg powder and solvent for prolonged-release suspension for injection

30 milligram(s) Powder and solvent for solution for injection

Teva B.V.PA1986/076/003

Main Information

Trade NameOlatuton 30 mg powder and solvent for prolonged-release suspension for injection
Active SubstancesOctreotide
Strength30 milligram(s)
Dosage FormPowder and solvent for solution for injection
Licence HolderTeva B.V.
Licence NumberPA1986/076/003

Group Information

ATC CodeH01CB Somatostatin and analogues
H01CB02 octreotide

Status

Authorised/WithdrawnAuthorised
Licence Issued19/08/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back